NCT06712459Recruiting
Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma
Summary
Histological transformation in Splenic Marginal Zone Lymphoma (t-SMZL) represents an unmet clinical and biological need, invariably associated with poor prognosis and reduced overall survival. At the present time, there are no recommended treatments intended specifically to t-SMZL and little is known about t-SMZL genetic complexity. The aim of this study is to provide information that will help clinicians to better understand the complexity of the disease. The information gained from this study will also lead to more specific and effective treatment for patients with t-SMZL.
Inclusion criteria
1. Adults aged 18 years or older, regardless of the gender; 2. Diagnosis of HT of SMZL (both at baseline, co-occurring with diagnosis of SMZL, or during the natural history of the disease); 3. Availability of diagnostic tumor material (either frozen or FFPE) from spleen, lymph node, extra nodal site, peripheral blood or bone marrow collected at the time of histological transformation. Tumor material (either frozen or FFPE), from spleen, peripheral blood or bone marrow, collected at the time of SMZL diagnosis will be also collected, if available; 4. Availability of the baseline and follow-up annotations.
Exclusion criteria
• None
Contacts
The trial team's contact details are shown on request.
See the official trial record- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Countries
- Switzerland, France, Italy, United States, Belgium, Spain, United Kingdom
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)(Other)
- Protocol no.
- IELSG54
- Conditions
- Transformed Splenic Marginal Zone Lymphoma
- Interventions
- —
Locations · 3
- Paris, FranceHôpital Saint LouisRecruiting at this site
- Pavia, ItalyFondazione IRCCS Policlinico San MatteoRecruiting at this site
- Barcelona, SpainHospital Clínic de BarcelonaRecruiting at this site
In total, worldwide, 3 of the 7 sites listed in the registry are recruiting; the other 4 are not currently recruiting.
Site status per the ClinicalTrials.gov registry (last update posted: January 16, 2026).
This status may have changed and says nothing about your eligibility: before taking any step, check with your oncologist or the site.
See also
Other versions
These results are indicative and do not replace medical advice — discuss them with your doctor.